• Drug Discovery Bundle See large image

    Drug Discovery Bundle (Hardback) By (author) Richard B. Silverman, By (author) Edward H. Kerns

    $158.66 - Save $35.11 18% off - RRP $193.77 Free delivery worldwide Available
    Dispatched in 1 business day
    When will my order arrive?
    Add to basket | Add to wishlist |

    DescriptionCombining two essential Academic Press books, this bundle provides reference information for drug discovery researchers and professionals at a great price. "Drug Like Properties" provides drug discovery scientists and students with a practical understanding of property fundamentals and structure modification strategies that can be applied to improving drug leads. "The Organic Chemistry of Drug Design and Drug Action" represents a new approach based on physical organic chemical principles and reaction mechanisms that allow the reader to extrapolate to many related classes of drug molecules.


Other books

Other people who viewed this bought | Other books in this category
Showing items 1 to 10 of 10

 

Reviews | Bibliographic data
  • Full bibliographic data for Drug Discovery Bundle

    Title
    Drug Discovery Bundle
    Authors and contributors
    By (author) Richard B. Silverman, By (author) Edward H. Kerns
    Physical properties
    Format: Hardback
    Weight: 2,976 g
    Language
    English
    ISBN
    ISBN 13: 9780123748676
    ISBN 10: 0123748674
    Classifications

    BIC E4L: SCI
    BIC subject category V2: PN
    Nielsen BookScan Product Class 3: S7.5
    BISAC V2.8: SCI013000
    Thema V1.0: PN
    Publisher
    Elsevier Science Publishing Co Inc
    Imprint name
    Academic Press Inc
    Publication date
    27 October 2008
    Publication City/Country
    San Diego
    Author Information
    Professor Richard B. Silverman received his B.S. degree in chemistry from The Pennsylvania State University in 1968 and his Ph.D. degree in organic chemistry from Harvard University in 1974 (with time off for a two-year military obligation from 1969-1971). After two years as a NIH postdoctoral fellow in the laboratory of the late Professor Robert Abeles in the Graduate Department of Biochemistry at Brandeis University, he joined the chemistry faculty at Northwestern University. In 1986, he became Professor of Chemistry and Professor of Biochemistry, Molecular Biology, and Cell Biology. In 2001, he became the Charles Deering McCormick Professor of Teaching Excellence for three years, and since 2004 he has been the John Evans Professor of Chemistry. His research can be summarized as investigations of the molecular mechanisms of action, rational design, and syntheses of potential medicinal agents acting on enzymes and receptors. His awards include DuPont Young Faculty Fellow (1976), Alfred P. Sloan Research Fellow (1981-1985), NIH Research Career Development Award (1982-1987), Fellow of the American Institute of Chemists (1985), Fellow of the American Association for the Advancement of Science (1990), Arthur C. Cope Senior Scholar Award of the American Chemical Society (2003), Alumni Fellow Award from Pennsylvania State University (2008), Medicinal Chemistry Hall of Fame of the American Chemical Society (2009), the Perkin Medal from the Society of Chemical Industry (2009), the Hall of Fame of Central High School of Philadelphia (2011), the E.B. Hershberg Award for Important Discoveries in Medicinally Active Substances from the American Chemical Society (2011), Fellow of the American Chemical Society (2011), Sato Memorial International Award of the Pharmaceutical Society of Japan (2012), Roland T. Lakey Award of Wayne State University (2013), BMS-Edward E. Smissman Award of the American Chemical Society (2013), the Centenary Prize of the Royal Society of Chemistry (2013), and the Excellence in Medicinal Chemistry Prize of the Israel Chemical Society (2014). Professor Silverman has published over 320 research and review articles, holds 49 domestic and foreign patents, and has written four books (The Organic Chemistry of Drug Design and Drug Action is translated into German and Chinese). He is the inventor of LyricaTM, a drug marketed by Pfizer for epilepsy, neuropathic pain, fibromyalgia, and spinal cord injury pain; currently, he has another CNS drug in clinical trials.